Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tydracin
- Development stage
- Unknown
- Lead developer
- Tygrus
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
**Tydracin** is an inhaled nebulized non-antibiotic respiratory therapeutic being developed by Miracus, a wholly owned subsidiary of Tygrus, for acute bacterial rhinosinusitis and acute viral rhinosinusitis. The product is based on Tygrus's proprietary Tydronium chemistry, described as stabilized proton acid chemistry intended to deliver broad-spectrum antimicrobial activity through a non-antibiotic mechanism, with reported preclinical activity against antimicrobial-resistant bacterial pathogens, viruses, and fungi. According to company materials, Phase 1 human testing was completed without adverse effects and a Phase 2 trial was launched in April 2025 in the Dominican Republic targeting sinusitis, positioning the program for broader respiratory infection applications.
- Brand names
- Tydracin
- Other names
- Tydronium-based nebulized solution
Beyond the preview
Go deeper on Tydracin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tydracin.